Despite Only Two Parallel Review Success Stories, CMS Touts Better Coordination
Executive Summary
While only two devices have received approval and a national coverage determination through US FDA/CMS' parallel review program, a top CMS official says industry needs to look beyond just the numbers. Instead, she says the parallel review program is part of a sea-change that has allowed for better communication between CMS, FDA and sponsors.
You may also be interested in...
US FDA Wades Into Reimbursement Issues With Upcoming Stakeholder Meeting On Alzheimer’s Drug Coverage, Evidence Challenges
Convened by the Duke-Margolis Health Policy Center, the meeting later this month will not be open to the public. But the center expects to continue to engage with stakeholders on the issues in the coming weeks and months.
Exact Launches Real-World Trial Of Cologuard Colon Cancer Screening
Exact Sciences Corp. and the Mayo Clinic are launching a 150,000-patient clinical trial examining the real-world effects of colorectal cancer screening with the Cologuard colon cancer test.
CMS Actively Looking For New Reimbursement Pathway For Innovative Devices
Industry is looking for a policy by the end of the year that would provide an automatic, temporary coverage pathway for breakthrough devices, and federal officials, including from the US Centers for Medicare and Medicaid Services (CMS) acknowledge they are actively looking at options for improving device reimbursement.